Podcasts about biotech

Artificial intelligence's rapid rise is causing anxiety for many, as it is already transforming the way we live and work. The concern is particularly high among young generations, who are wondering how it will change the labor market in the coming decades. But parents are also seeing the dangers AI and chatbots can pose as their children become more familiar with the technology. Jamie Metzl, a technology futurist and author of "Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World," recently spoke with FOX News Rundown's Lisa Brady to discuss AI and address some of the issues that make Americans nervous. Metzl delves into AI's evolution from its origins to today's consumer applications, and how future advancements may lead to job losses, reduced privacy, and even safety risks. He also talks about the good it can bring, especially in medicine. We often have to cut interviews short during the week, but we thought you might like to hear the full interview. Today on Fox News Rundown Extra, we will share our entire interview with AI expert Jamie Metzl. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to this episode of Hot Topics on the Edge of Show! Join hosts January Jones and Josh Krieger as they dive into the latest trends and challenges in the world of cryptocurrency with special guest Jack Ding from DomiChainIn this episode, we discuss:The trillion-dollar crypto chasm and the recent market fluctuations, including a significant loss of over $1 trillion in the crypto market since October 10th.The launch of Solana ETFs, which have seen remarkable success despite the overall market downturn.The formation of the Ethereum Protocol Advocacy Alliance and its potential impact on crypto regulation in Washington.The critical security vulnerabilities facing the rapidly growing DeFi sector, highlighted by recent hacks and the need for robust cybersecurity measures.How DomiChain is addressing the blockchain trilemma of scalability, security, and decentralization, and their innovative approach to enhancing security through AI and Bitcoin integration.Tune in for insightful discussions and expert perspectives on the future of blockchain technology and the evolving landscape of cryptocurrency. Don't forget to subscribe and follow us on your favorite platforms to stay updated on all things crypto!Support us through our Sponsors! ☕

Cells are the basic units of life. For over a century, understanding cellular processes has been the basis for understanding human development and disease, and for deciphering the actions of novel disease treatments. But there's a caveat: wet-lab studies in cells take time and money, they are often reductionist. To overcome those challenges of the wet lab, researchers have for some time tried to model cellular processes mathematically, in so-called virtual cells. With the availability of large-scale datasets and sophisticated AI models, virtual cells are advancing into useful tools for researchers. In episode 41 of the BioRevolution podcast we spoke to Prof. Fabian Theis, Chair of Mathematical Modeling of Biological Systems at TU Munich and director of the Institute of Computational Biology at the Helmholtz Zentrum München. With Fabian we discussed the convergence of mathematics and biology into virtual cell models and their potential use cases in basic research and drug development. You can find more on Fabian's research here: Theis Lab: https://www.helmholtz-munich.de/en/icb/research-groups/theis-lab Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

Democrats have scored major victories in key off-year elections, and democratic socialist candidate Zohran Mamdani's mayoral win in New York City could be shaking up the party's direction. Meanwhile, Republicans fell short in New Jersey and Virginia but are already looking ahead to the midterms. New York Republican Congressman Mike Lawler joins the Rundown to discuss what these results reveal about voter trends, how the GOP plans to regroup, plus the latest on the ongoing government shutdown as both parties face pressure to strike a deal. Artificial intelligence is rapidly transforming the way we live and work, sparking both excitement and concern about its impact on society, especially among younger generations growing up alongside it. Jamie Metzl, a technology futurist and author of "Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World," delves into AI's evolution from its origins to today's consumer applications. He also addresses the anxiety AI generates regarding job losses, privacy, and safety. Plus, commentary from commentary from Will Cain, host of FOX News Channel's The Will Cain Show and host of Will Cain Country on FOX News Audio. Learn more about your ad choices. Visit podcastchoices.com/adchoices

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mohammad Khan helps deep tech founders make their complex ideas understandable and compelling. But lately, he's been facing the same challenge he solves for others: how to articulate the unique value of his own work. When AI can write copy and marketing teams can polish messaging, where does his kind of storytelling fit?In this conversation, Mohammad and David uncover the real tension beneath that question: the difference between marketing a company and marketing the founder behind it. Together, they explore how the recognition and visibility comes from the story only you can tell.Because whether you're a founder, creator, or consultant, the hardest story to tell is often your own. But that's where your unique value lives.

Democrats have scored major victories in key off-year elections, and democratic socialist candidate Zohran Mamdani's mayoral win in New York City could be shaking up the party's direction. Meanwhile, Republicans fell short in New Jersey and Virginia but are already looking ahead to the midterms. New York Republican Congressman Mike Lawler joins the Rundown to discuss what these results reveal about voter trends, how the GOP plans to regroup, plus the latest on the ongoing government shutdown as both parties face pressure to strike a deal. Artificial intelligence is rapidly transforming the way we live and work, sparking both excitement and concern about its impact on society, especially among younger generations growing up alongside it. Jamie Metzl, a technology futurist and author of "Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World," delves into AI's evolution from its origins to today's consumer applications. He also addresses the anxiety AI generates regarding job losses, privacy, and safety. Plus, commentary from commentary from Will Cain, host of FOX News Channel's The Will Cain Show and host of Will Cain Country on FOX News Audio. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Um dos maiores desafios da imunoterapia é entender como o câncer consegue se esconder do próprio sistema imune.Neste episódio do podcast de Biotech and Health, Camila Pepe e Carolina Abelin conversam com a cientista Marcella Cardoso, da Harvard Medical School e do Massachusetts General Hospital, sobre novas descobertas na área oncológica. A pesquisadora explica como as chamadas células mieloides imunossupressoras (MDSCs) atuam para criar uma barreira protetora ao redor dos tumores, impedindo a ação das células de defesa. Segundo ela, compreender esses mecanismos de evasão imunológica é essencial para desenvolver terapias mais específicas e eficazes.Além da oncologia, a cientista acredita que o conhecimento obtido com novos estudos pode se expandir para outras áreas, como doenças autoimunes e inflamatórias.

Join us for an exciting episode of The Edge of Show, live from Token2049 in Singapore! In this episode, we dive deep into the evolving landscape of cryptocurrency and blockchain technology with Yat Siu, the chairman of Animoca Brands.We discuss the current regulatory climate and how it has opened new doors for tokenization, particularly in real-world assets (RWAs). We also explore the implications of hyperinflation in various countries and how cryptocurrencies serve as a hedge against economic instability.Later, we welcome Alok K Sinha, co-founder and chief ecosystem officer of Pazalabs, who shares the innovative work they are doing in real estate tokenization. Discover how they are revolutionizing the mortgage process and creating opportunities for global investors through blockchain technology.Finally, Keith Kim, COO of Nextbase, talks about the MapleStory Universe project and the integration of Web 3.0 elements into gaming. Learn about the potential of stablecoins in gaming and the shift towards mobile gaming experiences.Don't miss this insightful discussion on the future of finance, technology, and gaming!Support us through our Sponsors! ☕

In this episode of Tank Talks, host Matt Cohen sits down with Roberto Bellini, Co-Founder of BSQUARED Capital and former CEO of Bellus Health, for a powerful conversation about family, legacy, and resilience in the world of biotech.Originally recorded just two weeks before the passing of his father, Dr. Francesco Bellini, one of the founding giants of Canadian biotech, this re-recorded episode serves as a moving tribute to the man known as “Mr. Biotech Canada.” Roberto opens up about what it was like growing up under the guidance of such a visionary figure and how that experience shaped his own path as an entrepreneur and leader.He reflects on the highs and lows of leading Bellus Health, from moments of near collapse to its remarkable $2 billion acquisition by GSK, sharing lessons on risk-taking, perseverance, and the importance of staying grounded through uncertainty. Roberto also offers his perspective on the future of Canadian biotech, highlighting the need for stronger late-stage funding and how BSquared Capital is helping to cultivate the next generation of innovators.This episode isn't just about business success; it's about honoring a legacy, learning through adversity, and discovering what it truly means to build something that endures.The Legacy of Dr. Francesco Bellini (00:02:52)* Francesco Bellini's incredible immigrant story: from arriving in Canada with nothing to a $6B biotech exit.* Business was the family's dinner table conversation, and attending AGMs as a child.* The founding of Biochem Pharma and the discovery of the groundbreaking HIV treatment.* “He was a visionary... he saw things before other people saw them.”Growing Up in Biotech (00:06:30)* Roberto's early memories of board meetings and dinner-table business lessons* How being “in the room” shaped his entrepreneurial mindset* Watching a $6B biotech deal become part of family historyThe Rise, Fall, and Rebirth of Bellus Health (00:08:27)* Roberto's journey from family office analyst to a 30-year-old, first-time CEO of a public company.* The devastating failure of the phase three trial for a rare kidney disease.* Inside a Biotech Failure: The intense, weekend-long “war room” process of unblinding clinical trial data and preparing for a public announcement.The Second Act: Finding the Cough Drug (00:13:47)* Discovering a promising molecule through the NeoMed Institute* Betting the company's future on a last-chance asset* Raising $20M when no one believed and turning it into a $2B successNegotiating the GSK Deal (00:24:45)* The strategic shift from “build-to-sell” to “build-to-scale”, positioning the company for a premium acquisition.* The M&A Playbook: Why you should never lead with a desire to sell; the importance of building for independence.* The high-stakes negotiation with GSK: going from an $11 offer to $14.75, almost losing the deal, and the “mellow tone” that saved it.* The entrepreneur's dilemma: “Every single entrepreneur I've met that sold their company, there's always a moment of not wanting to do it.”Building Canada's Biotech Future (00:30:11)* Why Canada has the innovation but lacks the enduring biotech giants.* The critical gap: The need for more late-stage capital and the role of Canadian pension funds.* The “Gilead of the North” vision: Creating a virtuous cycle of capital, entrepreneurs, and translational science.* Upcoming trends: The convergence of AI and drug discovery to de-risk development and lower costs.Beyond the Lab: Leadership, Risk, and Legacy (00:46:20)* Learning to embrace risk and find joy in reinvention* The best advice from Dr. B: “Spend your money, it'll make you want to earn more.”* Why true success isn't just building a company, but building peopleAbout Roberto BelliniFounder & Managing Partner, BSQUARED CapitalRoberto Bellini is a second-generation biotech entrepreneur and investor. As the former CEO of Bellus Health, he led the company's dramatic turnaround and eventual $2 billion acquisition by GSK. Drawing on his deep operational experience in drug development, he now co-manages BSQUARED Capital, a family office focused on investing in and supporting promising biotech ventures. He is a passionate advocate for building a stronger, more resilient biotech ecosystem in Canada.Connect with Roberto Bellini on LinkedIn: https://www.linkedin.com/in/robertobellini/Visit BSQUARED Capital Website: https://bsq-c.com/Connect with Matt Cohen on LinkedIn: https://ca.linkedin.com/in/matt-cohen1Visit the Ripple Ventures website: https://www.rippleventures.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit tanktalks.substack.com

Synopsis: Jim Tananbaum, Founder & CEO of Foresite Capital, joins Rahul Chaturvedi to dissect the patterns driving biotech innovation, the role of macroeconomic cycles in venture performance, and how disciplined science fuels enduring investment success. Drawing from three decades across entrepreneurship and venture leadership, Jim reflects on his path from co-founding drug discovery startups with Harvard collaborators to building one of the most respected investment firms in life sciences. He unpacks how interest rate environments shape fund vintages, why AI is emerging as the next transformative platform, and how investors can identify enduring opportunities amid volatility. Their discussion spans valuation compression, AI-driven discovery, CNS and Alzheimer's innovation, and the geopolitical forces influencing biotech globally. Jim's perspective offers a masterclass in balancing scientific rigor with strategic foresight — and in positioning capital where breakthrough innovation meets sustainable impact. “Lean into areas where there's likely to be immense change,” Jim advises — a principle as relevant to biotech investing as it is to shaping the future of healthcare itself. Biography: Jim is the founder and CEO of Foresite Capital, a healthcare investment firm founded in 2011 that has approximately $3.5B in assets under management. Jim assembles the people, ideas, and money needed to launch products that save lives and improve healthcare. During the last three decades, Jim has been a thought partner for some of the fastest-growing companies of their generation, including 10x Genomics (Nasdaq: TXG), Amerigroup (Nasdaq: ANTM), and Jazz Pharmaceuticals (Nasdaq: JAZZ). Jim's entrepreneurial experience began at Harvard Business School when he co-founded GelTex Pharmaceuticals (Nasdaq:GENZ). With less than $80M in funding, GelTex brought two drugs to market, and the company was acquired in 1999 for $1.4B. Jim was also the founding chief executive of Theravance, Inc. Under his tenure, he raised over $350M. Theravance has since split into two parts, one of which is now part of GSK's respiratory franchise through a joint venture, Innoviva (Nasdaq: INVA), and the other was spun out into Theravance Biopharma, Inc. (Nasdaq: TBPH). Together, they achieved a market capitalization that exceeded $4B. Jim's investment experience includes co-founding Prospect Ventures and, earlier in his career, being a partner of Sierra Ventures, where he established its healthcare services investment practice. Jim graduated from Yale with a BS and BSEE in Applied Math and Electrical Engineering/Computer Science. He then earned an MD from Harvard, graduating from the Harvard/MIT HST Program. He also earned an MBA from Harvard while playing rugby.

Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences. What You'll Learn in This Episode: >> Why AI workloads in biotech demand specialized infrastructure >> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences >> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI >> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost >> Strategies for deploying, optimizing, and managing large-scale AI models Meet Our Guests Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction. Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Hugo Shi  on LinkedIn Connect with IIya Burkov on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Does networking stress you out? Are you having difficulty connecting with colleagues at conferences or partnering events? Mastering the art of genuine connection is essential to advancing your career and building your network. In this listener-favorite episode, James Zanewicz, JD, LLM, RTTP, and Elaine Hamm, PhD, dive deep into their personal strategies for networking success. With years of experience attending and producing biotech events, they share invaluable tips, insights, and even some humorous stories about their networking journeys—both the wins and the awkward moments. Whether you're an introvert looking for practical tips to step out of your comfort zone or an extrovert wanting to refine your approach, this episode offers something for everyone. In this episode, you'll discover: How to approach networking with authenticity, whether you're an introvert or extrovert. Tips on building genuine connections at biotech events and staying in touch after. Practical rules to position yourself to get the most out of networking, even if it's outside your comfort zone. Tune in to learn how to connect authentically, overcome social anxiety, and make the most out of your next networking opportunity. Links: Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development and the School of Medicine. Learn about James' first communications role: EXTRA! Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Timestamps:6:38 The birth of Cradle 21:36 Convincing Skeptics and Finding Product-Market Fit28:29 Raising Capital and Choosing the Right VCs35:21 Europe's missed opportunities (and how to fix them)Episode Summary:Stef Van Grieken, CEO and Co-founder of Cradle, the AI biotech startup helping scientists design better proteins in record time and pioneering the intersection of AI and biology, re-imagining how humans create life-changing molecules. Stef holds a MSc in Industrial Engineering from the University of Groningen . In this episode, Stef shares his journey from policy activism and Silicon Valley engineering to founding one of Europe's most ambitious deep-tech companies. We discuss how Cradle turned AI models into a tool for biologists, the hard early days when investors said “this is impossible,” and why the team literally paid its first customers to prove value before revenue followed.Stef also opens up about raising over $100 million, the three hypothesis you need to prove to create a disruptive startup (feasibility, value, monetization), navigating the gap between US and European venture cultures, and why Switzerland has everything needed to lead Europe's next innovation wave.This episode was sponsored by infinity.swiss, Switzerland's most advanced AI accounting tool. Save 25% by entering code SWISSPRENEUR at checkout.The cover portrait was edited by ⁠⁠⁠⁠⁠⁠⁠Smartportrait. ⁠⁠⁠⁠⁠‍Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Youtube ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode 472 features Dr. Sheila Gujrathi, a biotech entrepreneur, executive, and champion for under represented leaders. Her new book, "The Mirror Effect: A Transformative Approach To Growth For The Next Generation Of Female Leaders" is out now.Chapters:00:00 Introduction and Book Announcement02:15 The Unmet Need: Writing for My Younger Self05:30 Overcoming Challenges: A Personal Journey09:45 The Power of Mentorship and Sponsorship14:00 Spiritual Growth and Finding Purpose18:20 Building a Personal Board of Directors23:10 The Inner Critic and Self-Compassion28:45 The Importance of Storytelling in Leadership33:00 Navigating Negative Work Environments37:15 Conclusion: Embracing Vulnerability and ConnectionFind Sheila Online:Website: ​​https://sheilagujrathimd.com/ TEDxTalk: https://www.youtube.com/watch?v=2DpDx6T3-X4 LinkedIn: https://www.linkedin.com/in/sheila-gujrathi-md/ Instagram: https://www.instagram.com/sheilagujrathimd/ Book: https://sheilagujrathimd.com/book/ About Sheila:Sheila is a biotech entrepreneur, executive, and champion for under represented leaders. Over the past 25 years, she's had the privilege of developing life-changing medicines for patients with serious diseases while building and running private and public biotech companies—including some exciting exits. Today she's a founder, chairwoman, board director, strategic advisor, and consultant to start-up companies and investment funds. Dr. Gujrathi was the co-founder and former CEO of Gossamer Bio and former Chief Medical Officer of Receptos. Her journey started at Northwestern University, where she earned both her M.D. and biomedical engineering degree, and took her from the halls of Harvard, UCSF, and Stanford to the corporate offices of Fortune 500 companies like McKinsey, Genentech, and Bristol-Myers Squibb.Dr. Gujrathi has earned multiple leadership awards, including AIMBE Fellow, BLOC100 Luminary, Healthcare Technology Report Top 25 Women Leaders in Biotechnology, Corporate Directors Forum Director of the Year, and Fiercest Women in Life Sciences. But what really lights her up is creating the inclusive environments she wished she'd had throughout her career. That's why she co-founded the Biotech CEO Sisterhood, a group of trailblazing female CEOs—because we're all better when we support each other.

Welcome back to The Cinedicate. On today's episode, we're crash-landing into Alien: Earth, the first-ever Alien TV series. We break down the hybrid identity of Wendy, the corporate wars brewing between Weyland Yutani and Prodigy, and ask the big questions: What will humanity become when evolution and technology collide? Was Alien Earth a worthy addition to the Alien legacy, or just another xenomorph cash grab?So whether you're a lifelong Alien fan, love a good sci-fi debate, or just wonder what happens when memory itself becomes a weapon, join us as we dig through the wreckage and chart the future of the franchise—right here on The Cinedicate.What to expect from the episode:First impressions, debates, and generational perspectives on the new Alien: Earth TV series, including discussion on its connections to the classic films, franchise fatigue, and whether it brings anything new to the Alien universe.Deep dive into the show's major themes: AI consciousness, biotech, corporate power, and the ethics of uploading human minds into synthetic bodies, with comparisons to real-world technology and other sci-fi stories like Blade Runner and Altered Carbon.Spirited discussion on the show's structure, pacing, and narrative choices, including debates over fan service vs. originality, unresolved storylines, the impact of streaming models, and recommendations about whether Alien: Earth is a must-watch for Alien fans (or if you should just go watch Romulus or Blade Runner instead).Episode Chapters 00:00:00 - Introduction to Alien: Earth & Central Themes 00:01:47 - Personal Entry Points to Alien Franchise 00:08:29 - First Impressions - Alien: Earth00:11:31 - Series' Retro Aesthetic00:13:48 - Narrative Structure and Release Strategy 00:17:52 - Alien: Earth vs. Alien Romulus / Retreading Franchise Territory 00:20:40 - Hybrid Identity, Biotech, and AI in Alien: Earth00:30:33 - AI Sentience, Deception, and Control—Parallels to Reality 00:36:59 - Xenomorphs' Role: Gore, Threat, and Audience Expectations 00:39:50 - Timeline and Canon Questions00:43:17 - Other Alien Species: Significance, Motivation, and Unanswered Mysteries 00:46:35 - Desire for Narrative Closure: Open-Ended Finale Critique 00:49:13 - Themes of Power Transfer 00:50:43 - AVP/Potential Crossovers & Franchise-Building Speculation 00:55:53 - The Formula and Essence of an Alien Movie 01:02:42 - Ethical Debate: Should Humanity Weaponize Alien Life or Technology? 01:14:18 - Government vs. Corporation: Who Should Contain Biohazards? 01:17:43 - Alien: Earth in the Context of other Alien Media 01:27:20 - Final Judgment 01:29:49 - Outro Hosted on Acast. See acast.com/privacy for more information.

Charles River scientist Nicole Hoekstra, herself a US Navy veteran, used her employer-supported sabbatical to help out local Oklahoma based nonprofit Inner Circle Mental Health, which focuses on aiding veterans and first responders who are struggling with their mental health. I am joined by Nicole and ICMH founder Kate Cooper to discuss what this service means to both of them, how we can support family who are reluctant to accept help, and how the COVID pandemic impacted the mental health of first responders. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

Amid historic advances in cell-based therapies and precision medicine, biotech's biggest challenge isn't scientific, it's political. In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy, and grandson of FDR, as well as Advisory Board Member for Pluri Inc, discusses regulatory bottlenecks and their stalling effect on cell-based therapies, as well as the real dynamics behind FDA reform, and why biotech CEOs must become more fluent in policymaking now. You can listen to episode 215 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Die besten Aktien für die Zukunft: KI, Robotik & Biotech – die nächsten Tenbagger bis 2030? Wir stehen vor der nächsten großen Investment-Welle: Künstliche Intelligenz, Robotik, autonomes Fahren und Präzisionsmedizin verändern die Welt schneller, als je zuvor. Doch welche Aktien profitieren am meisten? Soundhound, Pony AI und Richtech Robotics sorgen an der Börse für Aufsehen. Sind das die neuen Nvidias und Palantirs – oder nur kurzfristige Hypes? Können diese Aktien wirklich 900% Rendite bis 2030 bringen? In diesem Video zeigen wir dir: ✅ Die stärksten Zukunftstrends – von Biotechnologie über Robotik bis KI ✅ 5 Aktien, die in den kommenden Jahren alles verändern könnten ✅ Welche Unternehmen echtes Potenzial haben – und welche du lieber meiden solltest ✅ Unsere Einschätzung: Langfristchance oder Risiko-Blase?

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company's thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Hunter Grad, CEO and founder of Ameliogenix, joins the show to talk about developing mRNA immunotherapies for cardiovascular disease. George K and George A sit down with Hunter to discuss: How a procrastinated university project turned into a biotech startup tackling the leading cause of death worldwide The novel application of mRNA technology to permanently reduce cholesterol levels through targeting proteins within the body rather than viral diseases What it takes to bootstrap a biotech company in Ottawa, not Silicon Valley The brutal realities of fundraising in biotech versus software startups, and why pivoting isn't always an option when lives are on the line Clearing up the myths and misinformation around mRNA technology, from how it actually works to addressing fertility concerns The role of machine learning in accelerating biotech research and drug discovery, and why quality data matters more than flashy AI hypeHunter breaks down complex immunology concepts into digestible explanations while sharing the raw challenges of being a young founder in a traditionally academic-led industry. This episode explores innovation at the intersection of technology and medicine, the importance of rigorous science over buzzwords, and what it means to swing for the fences on a problem that affects 2 billion people worldwide.Mentioned:Using AI, MIT researchers identify a new class of antibiotic candidates

In this edition of the Money Makers Investment Trusts Podcast, Jonathan Davis, editor of the Investment Trusts Handbook and winner of the AIC Best Broadcast Journalist Award for two years running (2024 and 2025), takes a look at the biotech sector and speaks to Woody Stileman, London officer manager at RTW Biotech, managers of RTW Biotech Opportunities (RTW); Geoffrey Hsu, manager of Biotech Growth Trust (IBT); and Ailsa Craig, co-manager of International Biotechnology Trust (BIOG). These conversations were recorded on Thursday 30 October 2025. Section Timestamps: 0:00:24 - Introduction 0:02:47 - Woody Stileman - RTW Biotech (RTW) 0:03:13 - - Why have biotech trusts been out of favour? 0:08:39 - - The involvement of AI 0:10:45 - - Appointments to the US Health Department and FDA 0:13:44 - - Drug pricing 0:18:33 - - RTW's private holdings and the IPO drought 0:22:13 - - The trust's discount 0:29:24 - - Risks in biotech 0:31:16 - A short break 0:32:22 - Geoffrey Hsu - Biotech Growth Trust (BIOG) 0:32:37 - - Explaining the biotech resurgence 0:40:25 - - Risks from an accelerated pipeline 0:41:42 - - The selling points of BIOG 0:44:32 - - Investing in China 0:47:18 - - UK interest in the sector 0:48:34 - Ailsa Craig - International Biotechnology Trust (IBT) 0:48:56 - - Looking at the changing fortunes of the biotechnology sector 0:54:26 - - The IBT difference to other trusts in the sector 0:57:09 - - The impact of the US drive to reduce drug prices 0:59:31 - - New drugs originating from biotech 1:03:26 - - Playing the China theme 1:04:53 - - Best use of capital 1:06:01 - - Capability of returns and position in the cycle 1:07:44 - - The change of management house 1:09:08 - Close If you enjoy the weekly podcast, you may also find value in joining The Money Makers Circle. This is a membership scheme that offers listeners to the podcast an opportunity, in return for a modest monthly or annual subscription, to receive additional premium content, including interviews, performance data, links to third party research, market/portfolio reviews and regular comments from the editor. A subscription costs £12 a month or £120 for one year. This week, as well as the usual features, the Circle features a profile of Seraphim Space Investment Trust (SSIT). Future profiles include Scottish American (SAIN) and Impax Environmental Markets (IEM). Our new expanded weekly subscriber email includes a comprehensive summary of all the latest news plus the week's biggest share price, NAV and discount movements. Subscribe and you will never miss any important developments from the sector. For more information please visit https://money-makers.co/circle. Membership helps to cover the cost of producing the weekly investment trust podcast, which will continue to be free for the foreseeable future. We are very grateful for your continued support and the enthusiastic response to our more than 300 podcasts since launch. You can find more information, including relevant disclosures, at www.money-makers.co. Please note that this podcast is provided for educational purposes only and nothing you hear should be considered as investment advice. Our podcasts are also available on the Association of Investment Companies website, www.theaic.co.uk. Produced by Ben Gamblin - www.bgprofessional.co.uk

In this Halloween-themed episode, Veronica Breckenridge from First Bite returns to discuss her eye-opening "Industrial Bio-Manufacturing Graveyard Report." Drawing from her experience scaling companies like Apple and Tesla, Veronica reveals why 80% of bio-manufacturing startups fail—and it's not because of bad science. The conversation explores critical mistakes like targeting commodity markets too early, underestimating downstream processing costs, and the "build it and they will come" mentality that has buried promising ventures. Veronica explains why now is actually the best time to invest in bio-manufacturing, citing decreasing costs (3 million times cheaper in 25 years), rising consumer demand for healthier alternatives to petroleum-based products, and increased government support for domestic manufacturing. She shares tactical advice on patient capital structures, the importance of strategic partnerships over going solo, and why bio-manufacturing is more analogous to hardware scaling than pharmaceutical development. The episode offers valuable lessons for founders, investors, and anyone interested in the future of sustainable manufacturing.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Halloween intro and SNL's Snack Homies discussion(00:04:17) - Zombie apocalypse: Could fungi or viruses cause real zombies?(00:09:12) - Beyond Meat stock surge and meme trading(00:11:34) - Introducing the Graveyard Report and Veronica Breckenridge(00:14:23) - Why Veronica moved from Tesla to bio-manufacturing(00:19:45) - The three recurring market fit errors killing startups(00:27:56) - Why targeting commodity markets is a seductive trap(00:35:18) - Downstream processing: The overlooked cost killer(00:42:31) - CapEx overruns and the importance of strategic partnerships(00:48:07) - Patient capital structures for deep tech ventures(00:53:22) - What makes this moment different: Why invest now(00:58:14) - Quick fire questions and closing thoughtsLinks and Resources:First BightThe Industrial Biomanufacturing Graveyard ReportBiowell Biotech AcceleratorGinkgo ConsultingCapgeminiMcKinsey120. Busting Biotech's Bottlenecks: Veronica Breckenridge on the Path to Industrial Scale151. Report on Reports: Cash Flow, Carbon, and the BioeconomyZombie-like effects from fungusBeyond Meat's Stock SpikeTedX BostonTechnoeconomic Analysis Tool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Topics Covered: industrial biomanufacturing, biotech, business, growth stage, graveyard report, halloweenHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year’s graveyard, including a cell therapy mausoleum, some mad science, and Darren’s incredibly dated reference to a novelty song from 1958. To learn more about the topics in this episode: The 2025 Biotech Graveyard See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reaching $10 billion in a single quarter. This success can be attributed to Lilly's innovative direct-to-consumer sales strategy, which exemplifies how modern marketing approaches can overcome traditional market barriers. Additionally, Eli Lilly's partnership with Walmart to expand access to Zepbound through retail pharmacy pickups exemplifies a strategic approach to enhancing patient access to crucial medications. By leveraging Walmart's extensive retail network, this collaboration facilitates easier access to obesity treatments—a significant public health challenge—enhancing both patient convenience and broadening market reach for Lilly's products. These achievements not only highlight the potential of strategic marketing but also underscore a growing demand for effective obesity treatments within the pharmaceutical industry.In another exciting development, Alnylam Pharmaceuticals has reported impressive sales figures for Amvuttra, a treatment for transthyretin amyloid cardiomyopathy. Surpassing analysts' expectations, this success signals a growing market for treatments targeting rare diseases and emphasizes the importance of strategic market expansion to reach underserved patient populations.Meanwhile, Bristol Myers Squibb's anticipated schizophrenia treatment, Cobenfy, has experienced a lukewarm market entry. While meeting initial expectations in its first year, it has yet to create the breakthrough impact investors anticipated. This situation highlights the challenges even well-hyped pharmaceuticals face upon launch and underscores the need for continuous strategic planning to ensure market penetration and sustained growth.A surprising development in mergers and acquisitions comes from Novo Nordisk's $6.5 billion counteroffer to acquire Metsera, an obesity biotech initially targeted by Pfizer. This aggressive move reflects intense competition in the obesity drug market and illustrates the high stakes involved in acquiring promising biotech assets that could potentially transform treatment paradigms for chronic conditions like obesity.The vaccine industry is navigating its own set of challenges with declining sales across the board. However, Merck's adult pneumococcal vaccine Capvaxive has shown promising initial sales figures. As the first pneumococcal vaccine specifically designed for adults, Capvaxive indicates a potential niche market that Merck could successfully capture.On the regulatory front, significant measures are being taken by the FDA to boost biosimilar availability against drug pricing pressures. New draft guidance aims to eliminate clinical testing requirements for biosimilars and categorize all approved biosimilars as "interchangeable." This initiative could significantly reduce biologic medicine costs post-patent expiration and increase competition in the market, potentially making essential medications more accessible to patients. Additionally, the FDA is proposing streamlined biosimilar approval pathways aimed at reducing overall bio-drug costs—a welcome move reflecting concerted efforts to make essential medications more affordable and accessible globally.Argenx has reported positive trial results for Vyvgart in treating generalized myasthenia gravis (gMG), highlighting its commitment to addressing unmet needs within this patient population. These findings could expand treatment options for gMG patients who have been previously overlooked in thSupport the show

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?David: Unlocking potential.Biotech startups face daunting challenges, but David Kiewlich, Founder and CEO of Tomorrow Biotech Corporation, has created a model that flips the odds. While most startups face a 90% failure rate, David's incubator, Badass Labs, boasts an astounding 95% success rate.The secret? David's incubator takes on time-consuming tasks and provides founders with the tools and support they need to focus on high-value activities. “We take what I call low-value, high-risk tasks off of the responsibility of these early founders,” David explained. By handling procurement, accounting, and regulatory compliance, the incubator saves startups time, money, and frustration.For example, David shared how the incubator's full-service procurement system saves companies more than 70 hours of work while also cutting costs. “Because it's a pooled spend model, it allows us to be one giant customer instead of many little ones,” he said. This approach not only improves efficiency but also doubles the runway for many startups.David's focus goes beyond logistics—he's also deeply invested in coaching founders to grow. He emphasized the importance of coachability, saying, “If they are open to guidance and comfortable with being vulnerable, they'll grow.” This hands-on support ensures founders avoid rookie mistakes, expand their skill sets, and present their companies as professional and investor-ready.The work being done at Badass Labs and Tomorrow Biotech isn't just about improving success rates—it's about saving lives. By accelerating the development of biotech innovations, David's incubator is paving the way for groundbreaking ideas to reach the market faster.If you're inspired by David's approach and want to learn more about his incubator, visit badasslabs.org. With multiple locations across the U.S. and plans to expand, the program is open to biotech, climate tech, and other transformative startups. By helping founders focus on what matters most, David is proving that with the right support, startups can defy the odds and change the world.tl;dr:David Kiewlich's incubator flips the biotech startup success rate from 10% to 95% with unique support.The program removes tedious tasks, saving founders time and enabling them to focus on execution.Coachability is critical—David helps founders grow by fostering their confidence and guiding their development.David shared a superpower: unlocking potential by building up others and inspiring action.Tomorrow Biotech and Badass Labs accelerate innovation, empowering founders to bring life-saving ideas to market.How to Develop Unlocking Potential As a SuperpowerDavid Kiewlich's superpower is his ability to unlock the potential in others by fostering their confidence and helping them grow into their best selves. Reflecting on his life, David shared how he developed this skill early on, saying, “You become sort of focused on how you can lift up and protect everyone around you.” He uses this mindset to empower biotech founders, helping them become “superhumans” who think bigger, execute better, and achieve more.One inspiring story David shared highlights his superpower in action. Years ago, he organized a grassroots effort to rescue surplus food from wholesalers and deliver it to nonprofits across the San Francisco Bay Area. Over the course of a year, he single-handedly moved nearly 600,000 pounds of produce, ensuring it reached those in need instead of ending up in landfills. By showing what's possible, David inspired others to replicate his efforts, amplifying his impact.To develop this superpower, David suggests:Focus on building up others rather than seeking credit for yourself.Encourage people by expressing belief in their abilities.Help others see what's possible by setting an example.Support people in a way that allows them to focus on their strengths.By following David's example and advice, you can make unlocking potential a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDavid Kiewlich (he/him):Founder and CEO, Tomorrow Biotech CorporationAbout Tomorrow Biotech Corporation: Tomorrow Biotech Corporation consists of an accelerator fund, an early stage fund and includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators. While the funds are new, the incubator has been in operation for 6 years, supporting dozens of pre-seed through series B (and beyond) companies. With a track record of 50 of 55 company successes for members of the incubator, this ecosystem has a uniquely successful approach to founder support, which has substantially changed the concept and expectations for early stage incubators. BADASS Labs is more than a 501c3, non-profit biotech incubator that rents lab space to small businesses. It is a strategic ally that empowers biotech entrepreneurs to achieve their full potential. By offering a comprehensive suite of services, such as purchasing, waste management, operations and even health insurance plans for its members, BADASS Labs enables its clients to focus on their core competencies and substantially reduce their operational costs. BADASS Labs bridges the gap between research and commercialization, by facilitating novel technologies from academic, national lab or self-generated sources into viable products that can enhance the domestic supply chain and generate regional employment. While we can incubate companies at any stage, we have a particular focus on the earlier side, from Pre-Seed through Series B stages.Website: badasslabs.org, TomorrowBiotech.com, MissionBoosterProcurement.comBiographical Information: Dr. David Kiewlich (Ph.D. in Cell and Developmental Biology) is a serial founder and entrepreneur in biotech. With over 35 years' experience working for industry, as well as 6 startups of his own (in Oncology, Cell Based Therapies and Synthetic Biology), his background is excellently aligned with the needs and struggles of pre-commercialization startups. He founded and runs Tomorrow Biotech, which includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators, which has supported dozens of pre-seed through series B (and beyond) companies, as well as a startup and early-stage fund. In addition to Tomorrow Biotech, David is also the CSO of a cell based therapy company, focused on autoimmune disease, advisor for several biotech startups and frequent public speaker advocating for increased sustainability and greater Diversity, Equity and Inclusion (DEI) in the sciences.LinkedIn Profile: linkedin.com/in/davidkiewlichSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and Rancho Affordable Housing (Proactive). Learn more about advertising with us here to help us Power Up October.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on October 28, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, November 19, 2025, at 12:00 PM Eastern — Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “Investing with a Self-Directed IRA.” In this session, Devin will explain how investors can use self-directed IRAs to participate in regulated investment crowdfunding while managing taxes and optimizing returns. He'll break down when this strategy makes sense, how to choose the right custodian, and what fees, rules, and risks to watch for. With his trademark clarity and real-world experience, Devin will help you understand how to balance simplicity with smart tax planning—so you can invest confidently, align your portfolio with your values, and make your money work harder for both impact and income.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Impact Accelerator Summit is a live, in-person event taking place in Austin, Texas, from October 23–25, 2025. This exclusive gathering brings together 100 heart-centered, conscious entrepreneurs generating $1M+ in revenue with 20–30 family offices and venture funds actively seeking to invest in world-changing businesses. Referred by Michael Dash, participants can expect an inspiring, high-impact experience focused on capital connection, growth, and global impact.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Our Head of Corporate Credit Research Andrew Sheets explains why the recent revival of M&A activity has room to accelerate.Read more insights from Morgan Stanley.----- Transcript -----Andrew Sheets: Welcome to Thoughts on the Market. I'm Andrew Sheets, Head of Corporate Credit Research at Morgan Stanley. Today – a discussion of merger and acquisition activity or M&A. Last year, we had a view that this activity would pick up significantly. We think we're seeing that increase now. It has further to go. It's Wednesday, October 29th at 2pm in London. We have been firm believers at Morgan Stanley in a significant multi-year uplift in global merger and acquisition activity or M&A. That conviction remains. The incentives for this type of action are strong in our view; activity still lags what fundamentals would suggest, and supportive regulatory shifts are real. M&A has now returned, and importantly, we think there's much further to go. Indeed, M&A is very closely linked to corporate confidence, and we think investors need to consider the possibility that we'll see an even bigger surge in this confidence – or a boom. First, policy uncertainty is declining as U.S. tax legislation has now passed, and tariff rates get finalized. It's the relative direction of this uncertainty that we think matters most for corporate confidence. Second, interest rates are declining with the Fed, European Central Bank, and Bank of England all set to cut rates further over the next 12 months. Third, bank capital requirements may decline in the view of Morgan Stanley analysts, which would unlock more lending for these types of transactions. Fourth, and very importantly, the regulatory backdrop is becoming more accommodative in both the U.S. and in Europe. Indeed, we think that companies may think that this is going to be the most permissive regulatory window for transactions that they might get for some time. Fifth, private equity, which is a big driver of M&A activity, is sitting on over $4 trillion of dry powder in our view – at a time when credit markets look very wide open for financing their transactions. And finally, we're seeing a surge in capital expenditure on Morgan Stanley estimates, which we see as a sign of rising corporate confidence, and importantly an urgency to act – with corporates far less content to simply sit back and repurchase their stock. All of these favorable conditions together argue for activity to push even higher. We forecast global M&A volumes to increase by 32 percent this year, an additional 20 percent next year, and reach $7.8 trillion in volume in 2027. This is a global story with M&A rising across regions, especially in Japan. It has cross-asset implications with M&A already being one of the biggest drivers of bond outperformance within the U.S. high-yield market. And this is also a story where we see a lot of value in bringing together macro and micro perspectives. While we think the top-down conditions look favorable for all the reasons I just mentioned, we also see a very encouraging picture bottom up. We polled a large number of Morgan Stanley sector analyst teams and asked them about M&A conditions in their sector. A large majority of them see more activity. So, where could these more specific implications lie? Well, as you heard on yesterday's episode, Healthcare and Biotech may see an uptick in activity. In the U.S., we also think that Banking and Media stand out. In Europe, Business Services, Metals and Mining, and Telecom seem most ripe for more M&A. Aerospace and Defense is an interesting sector that may see more M&A within multiple regions, including the U.S. and Europe, as companies look for scale. And with smaller companies trading at a valuation discount to their larger peers across the world, Morgan Stanley analysts generally see the strongest case for activity in larger companies acquiring these smaller ones. Thank you as always for your time. If you find Thoughts on the Market useful, let us know by leaving a review wherever you listen, and also tell a friend or colleague about us today.

Recorded live at the Input Whispers: Jazz and Cigars event in Singapore, this special compilation episode created in partnership with Input PR, brings together four insightful conversations exploring the evolving frontiers of Web3, tokenization, fraud prevention, payments, and digital security.In this exclusive collection, co-host Josh Kriger sits down with some of the leading minds shaping the future of blockchain:Edwin Mata, CEO and co-founder of Brickken, on how Real World Assets (RWAs) and tokenization are revolutionizing capital markets and democratizing investment access.Pascal Podvin, co-founder and CRO of Nsure.ai, on leveraging AI to fight fraud and strengthen KYC in an increasingly complex crypto ecosystem.Konstantins Vasilenko, co-founder and CBDO of Paybis, on simplifying crypto onboarding, bridging fiat and digital currencies, and the global rise of crypto debit cards and stablecoins.Alex Katz, co-founder and CEO of Kerberus, on redefining real-time Web3 security, achieving zero user losses, and setting new standards for digital trust.From tokenized assets to next-generation security and payments, this episode captures the dynamic pulse of Web3 innovation straight from Singapore's vibrant crypto scene.Support us through our Sponsors! ☕

Sylke Poehling didn't set out to lead one of the world's most advanced gene therapy companies - but a love for drug discovery and a career built on curiosity, courage and conviction brought her there.  Now CEO of Spark Therapeutics and SVP at Roche, Sylke joins us on Careers in Discovery to share her journey from academia into Biotech, how Spark pioneered the world's first FDA-approved directly administered gene therapy, and what it means to build the next generation of treatments - and the company culture to deliver them.  She reflects on what it takes to lead through risk and uncertainty, how to balance scientific ambition with operational focus, and why authenticity and clarity are at the heart of impactful leadership.  An inspiring conversation with a scientist-turned-CEO who's still pushing boundaries and redefining what's possible in genetic medicine. 

Medical Affairs isn't a downstream function—it's the throughline connecting science, story, and strategy from development through commercialization. This episode features Howard Rutman, MD, MBA, Chief Medical Officer at Xalud Therapeutics and Peg Crowley-Nowick, PhD, MBA discussing the critical role of early Medical Affairs engagement. Key topics include how early Medical Affairs involvement speeds patient enrollment and data generation, qualities to seek in the first Medical Affairs hire, the value a lean team can bring to BioTech, and the importance of evidence plans that support physician and market access needs.  The podcast emphasizes Medical Affairs as a continuous link from development to commercialization.

The U.S. inked Technology Prosperity Deals (TPD) with Japan and South Korea with an eye towards spurring collaboration on AI, semiconductors, quantum computing, biotech, space, 6G and other technologies. Character AI is ending its chatbot experience for kids. After facing lawsuits and public outcry following the suicides of two teenagers, Character.AI says it's making changes to its platform to protect children, changes that could affect the startup's bottom line. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Zowel goud als zilver zijn bij beleggers in trek de laatste jaren. Danny Reweghs zet de twee tegen elkaar af in een ultiem duel rond welk van de twee het interessantst is. Daarnaast vertelt hij over de teleurstelling bij biotechspeler Galapagos en successen van palmolieproducent Sipef. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie. De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst. Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen. Onafhankelijk, relevant, telkens constructief en toekomstgericht. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.Read more insights from Morgan Stanley.----- Transcript -----Sean Laaman: Welcome to Thoughts on the Market. I'm Sean Laaman, Morgan Stanley's U.S. Small and Mid-Cap Biotech Analyst. Terence Flynn: And I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst. Sean Laaman: Today, we'll discuss how a rally in the healthcare sector is being driven by more favorable macro conditions. It's Tuesday, October 28th at 10am in New York. So, Terence, healthcare has lagged the broader market year-to-date, and valuations have been near historical lows. But recent weeks show strengthening performance. Policy headwinds have been front and center.What's changed in the regulatory environment and how is the biopharma sector adapting to these pricing and tariff dynamics? Terence Flynn: Sean, as you know, with many other sectors, tariffs were initially a focus earlier this year. But a number of companies in our space have subsequently announced significant U.S. manufacturing investments to reshore supply chains. And hence, the market's less focused on tariffs in our space right now. But the other policy dynamic and focus is what's called Most Favored Nation or MFN drug pricing. Now, this is where the President's been focused on aligning U.S. drug prices with those in other developed countries. And recently we've seen several companies announce agreements with the administration along these lines, which importantly has provided investors with more visibility here. And we're watching to see if additional agreements get announced. Sean Laaman: Got it. Another hurdle for Large-cap biopharma is a looming expiration of patents with [$]177 billion exposed by 2030. How is this shaping M&A trends and strategic priorities? Terence Flynn: For sure. I mean, as you know, Sean, patent expiry is our normal part of the life cycle of drug development. Every company goes through this at some point, but this does put the focus on company's internal pipelines to continue to progress while also being able to access external innovation via M&A. Recently we have started to see a pickup in deal activity, which could bode well for performance in SMID-cap biotech. Sean Laaman: At the same time, you believe relative valuations look compelling for Large-cap biopharma. Where are valuations versus where they've been historically? What's driving this and how should investors think about positioning? Terence Flynn: Absolutely. Look, on a price to earnings multiple, the sector's trading at about a 30 percent discount to the S&P 500 right now. Now that's in line with prior periods of policy uncertainty. But as policy visibility improves, we expect the focus will shift back to fundamentals. Now, positioning to me still feels light here, given some of the patent cliff dynamics we just discussed. Now, Sean, with the Fed moving toward rate cuts, how do you see this impacting your sector on the biotech side? Sean Laaman: Well, Terence, particularly in my space, which is Small- and Mid-cap biotech companies, they're typically capital consumers are not capital producers. They're particularly sensitive to the current rate environment.Therefore, they're sensitive to spending on pipeline. They're sensitive to M&A. So, as rates come down, we expect more spending on pipeline and more M&A activity, which is generally positive for the sector. Looking forward, biotech sector is generally the best performing sector on a six-to-12-month timeframe post the first rate cut. Terence Flynn: Great. You've also talked about this SMID to Big thesis on the biotech side. Can you explain what's driving that? Sean Laaman: Sure Terence. There's three pieces to the SMID to Big thematic. So, we in SMID-cap biotech, we cover 80 to 90 companies. About a third of those are newly, kind of profitable companies. Those companies are turning from being capital consumers to capital producers. We see about $15 billion of cash on balance sheets for 2025, going to north of 130 billion by 2030. That's the first piece. The second piece is due to regulatory uncertainty at the USFDA. We're seeing more attractive valuations amongst clinical stage names. That's the second piece. And third piece relates to your coverage, Terence. I refer back to that [$]177 billion of LOE. So, we expect generally that M&A activity will be quite high amongst our sector. Terence Flynn: And let's not forget about AI, which has implications across the healthcare space. How much is this changing the dynamic in biotech, Sean? Sean Laaman: It is changing, but we're really at the beginning. I think there's three things to think about. The first one is faster trial recruitment. The second one is faster regulatory submissions. And the third one, which is the most interesting, but we're really at the beginning of, is faster time to appropriately targeted molecules. Terence Flynn: Great. And maybe lastly, what are the key risks and catalysts for SMID-cap biotech in the current environment? Sean Laaman: As always, we're focused on pipeline failures in terms of risk. Secondly, in terms of risk, we're looking at regulatory risk at the FDA. And thirdly, we're looking at the rise in China biotech and the competitive dynamic there.Whether you're watching large cap biopharma, M&A moves, or the rise of cash-rich, SMID-cap biotechs, the healthcare sector setup is unlike anything we've seen in years.Terence, thanks for speaking with me. Terence Flynn: Always a pleasure to be on the show. Thanks for having me, Sean. Sean Laaman: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?David: Unlocking potential.Biotech startups face daunting challenges, but David Kiewlich, Founder and CEO of Tomorrow Biotech Corporation, has created a model that flips the odds. While most startups face a 90% failure rate, David's incubator, Badass Labs, boasts an astounding 95% success rate.The secret? David's incubator takes on time-consuming tasks and provides founders with the tools and support they need to focus on high-value activities. “We take what I call low-value, high-risk tasks off of the responsibility of these early founders,” David explained. By handling procurement, accounting, and regulatory compliance, the incubator saves startups time, money, and frustration.For example, David shared how the incubator's full-service procurement system saves companies more than 70 hours of work while also cutting costs. “Because it's a pooled spend model, it allows us to be one giant customer instead of many little ones,” he said. This approach not only improves efficiency but also doubles the runway for many startups.David's focus goes beyond logistics—he's also deeply invested in coaching founders to grow. He emphasized the importance of coachability, saying, “If they are open to guidance and comfortable with being vulnerable, they'll grow.” This hands-on support ensures founders avoid rookie mistakes, expand their skill sets, and present their companies as professional and investor-ready.The work being done at Badass Labs and Tomorrow Biotech isn't just about improving success rates—it's about saving lives. By accelerating the development of biotech innovations, David's incubator is paving the way for groundbreaking ideas to reach the market faster.If you're inspired by David's approach and want to learn more about his incubator, visit badasslabs.org. With multiple locations across the U.S. and plans to expand, the program is open to biotech, climate tech, and other transformative startups. By helping founders focus on what matters most, David is proving that with the right support, startups can defy the odds and change the world.tl;dr:David Kiewlich's incubator flips the biotech startup success rate from 10% to 95% with unique support.The program removes tedious tasks, saving founders time and enabling them to focus on execution.Coachability is critical—David helps founders grow by fostering their confidence and guiding their development.David shared a superpower: unlocking potential by building up others and inspiring action.Tomorrow Biotech and Badass Labs accelerate innovation, empowering founders to bring life-saving ideas to market.How to Develop Unlocking Potential As a SuperpowerDavid Kiewlich's superpower is his ability to unlock the potential in others by fostering their confidence and helping them grow into their best selves. Reflecting on his life, David shared how he developed this skill early on, saying, “You become sort of focused on how you can lift up and protect everyone around you.” He uses this mindset to empower biotech founders, helping them become “superhumans” who think bigger, execute better, and achieve more.One inspiring story David shared highlights his superpower in action. Years ago, he organized a grassroots effort to rescue surplus food from wholesalers and deliver it to nonprofits across the San Francisco Bay Area. Over the course of a year, he single-handedly moved nearly 600,000 pounds of produce, ensuring it reached those in need instead of ending up in landfills. By showing what's possible, David inspired others to replicate his efforts, amplifying his impact.To develop this superpower, David suggests:Focus on building up others rather than seeking credit for yourself.Encourage people by expressing belief in their abilities.Help others see what's possible by setting an example.Support people in a way that allows them to focus on their strengths.By following David's example and advice, you can make unlocking potential a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDavid Kiewlich (he/him):Founder and CEO, Tomorrow Biotech CorporationAbout Tomorrow Biotech Corporation: Tomorrow Biotech Corporation consists of an accelerator fund, an early stage fund and includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators. While the funds are new, the incubator has been in operation for 6 years, supporting dozens of pre-seed through series B (and beyond) companies. With a track record of 50 of 55 company successes for members of the incubator, this ecosystem has a uniquely successful approach to founder support, which has substantially changed the concept and expectations for early stage incubators. BADASS Labs is more than a 501c3, non-profit biotech incubator that rents lab space to small businesses. It is a strategic ally that empowers biotech entrepreneurs to achieve their full potential. By offering a comprehensive suite of services, such as purchasing, waste management, operations and even health insurance plans for its members, BADASS Labs enables its clients to focus on their core competencies and substantially reduce their operational costs. BADASS Labs bridges the gap between research and commercialization, by facilitating novel technologies from academic, national lab or self-generated sources into viable products that can enhance the domestic supply chain and generate regional employment. While we can incubate companies at any stage, we have a particular focus on the earlier side, from Pre-Seed through Series B stages.Website: badasslabs.org, TomorrowBiotech.com, MissionBoosterProcurement.comBiographical Information: Dr. David Kiewlich (Ph.D. in Cell and Developmental Biology) is a serial founder and entrepreneur in biotech. With over 35 years' experience working for industry, as well as 6 startups of his own (in Oncology, Cell Based Therapies and Synthetic Biology), his background is excellently aligned with the needs and struggles of pre-commercialization startups. He founded and runs Tomorrow Biotech, which includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators, which has supported dozens of pre-seed through series B (and beyond) companies, as well as a startup and early-stage fund. In addition to Tomorrow Biotech, David is also the CSO of a cell based therapy company, focused on autoimmune disease, advisor for several biotech startups and frequent public speaker advocating for increased sustainability and greater Diversity, Equity and Inclusion (DEI) in the sciences.LinkedIn Profile: linkedin.com/in/davidkiewlichSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and Rancho Affordable Housing (Proactive). Learn more about advertising with us here to help us Power Up October.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on October 28, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, November 19, 2025, at 12:00 PM Eastern — Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “Investing with a Self-Directed IRA.” In this session, Devin will explain how investors can use self-directed IRAs to participate in regulated investment crowdfunding while managing taxes and optimizing returns. He'll break down when this strategy makes sense, how to choose the right custodian, and what fees, rules, and risks to watch for. With his trademark clarity and real-world experience, Devin will help you understand how to balance simplicity with smart tax planning—so you can invest confidently, align your portfolio with your values, and make your money work harder for both impact and income.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Impact Accelerator Summit is a live, in-person event taking place in Austin, Texas, from October 23–25, 2025. This exclusive gathering brings together 100 heart-centered, conscious entrepreneurs generating $1M+ in revenue with 20–30 family offices and venture funds actively seeking to invest in world-changing businesses. Referred by Michael Dash, participants can expect an inspiring, high-impact experience focused on capital connection, growth, and global impact.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Most founders dream of raising millions. Few survive the 153 “no's” it takes to get there.Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line.What separates the ones who make it isn't luck or timing — it's resilience built into process.In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart.You'll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades. If you've ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it's a practice.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show

Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.

AI is transforming biotechnology from the inside out. What was once a world of petri dishes and pipettes is now increasingly powered by algorithms, models, and digital twins. But as machine learning accelerates drug discovery and reshapes clinical trials, how far can we go before biology itself becomes the follower, not the leader?In this episode of Tech Tomorrow, David Elliman speaks with Bibi Ephraim, Head of Digital Sciences at Genentech, about how artificial intelligence is redefining the biotech landscape. They explore how data-driven approaches are rapidly compressing timelines in drug discovery, enabling precision medicine, and even simulating virtual clinical trials.They also tackle the cultural and organisational transformations needed to make digital biotech work; from breaking down data silos and fostering collaboration across competitors, to treating data as a product and investing in strong governance. Drawing parallels with digital transformation in other industries, they ask what it will take for biotech to move from project-based to product-based innovation, and why pre-competitive collaboration could unlock the next generation of cures.Episode Highlights:01:40 – What do AI, data science, and digital governance in the biotech landscape look like today?03:06 – Biotech and the data foundations needed for transformation.04:52 – Examples of successful data-driven approaches in biotech.08:10 – Will parts of the medical process be completely handed over to AI?09:39 – David's thoughts: The importance of sustained, iterative innovation.11:49 – The biggest mistake Bibi sees executives make in relation to data.13:08 – The huge issue of low-quality data.14:59 – Data sharing is critical in this field.19:03 – David's thoughts: How pre-competitive collaboration benefits everyone.21:17 – Is biotech reaching a standardisation tipping point?24:11 – Can biotech scale digitally and effectively?26:30 – Will the next biotech breakthrough be digital before it's biological?28:33 – If digitalisation expands, will researchers miss the “happy accidents” of drug discovery?About Zühlke:Zühlke is a global transformation partner, with engineering and innovation at its core. We help clients envision and build their businesses for the future – running smarter today while adapting for tomorrow's markets, customers, and communities.Our multidisciplinary teams specialise in technology strategy and business innovation, digital solutions and applications, and device and systems engineering. We thrive in complex, regulated sectors such as healthcare and finance, connecting strategy, implementation, and operations to help clients build more effective and resilient businesses.Links:Zühlke WebsiteZühlke on LinkedInDavid Elliman on LinkedInBibi Ephraim on LinkedInGenentech Website

A $40 million partnership with Buffalo Trace is giving new life to one of bourbon's biggest byproducts: stillage.In this episode, Meridian Biotech founder Brandon Corace joins us to share how his company is transforming distillery waste into sustainable products that fuel industries like aquaculture, pet food, and fertilizer. From winning a “reverse pitch” competition with the Governor's Office to relocating from Austin to Lexington, Brandon's story shows how innovation, biotech, and Kentucky's bourbon heritage are coming together to create the state's next major industry.Hosted by Logan JonesMiddle Tech is proudly supported by:KY Innovation → kyinnovation.comAwesome Inc → awesomeinc.org

We love to hear from our listeners. Send us a message. On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's editorial advisory board and Miami-based location host for our in-person series. Rich talks about Catalyst's rare disease strategy built on operational excellence (including how to select a rare disease special pharmacy), his criteria for selecting de-risked, differentiated, and accretive products for rare diseases, partnering outside the U.S., and what new incentives Florida politicians could create to help South Florida grow even faster as a life sciences hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

For episode 618 of the BlockHash Podcast, host Brandon Zemp is joined by Christian Davies, Global Head of Distribution and Innovation for Relm. Christian Davies has over 12 years of experience in the insurance industry as a worldwide brokerage executive director and founder. He drives Relm’s global distribution strategies and fosters innovation to enhance product reach and market impact. Relm crafts insurance solutions that give businesses in dynamic industries like Web3, AI, Alternative Medicine, Biotech and the Space Economy the protection to innovate and thrive. ⏳ Timestamps: (0:00) Introduction(1:07) Who is Christian Davies?(11:07) How to keep up with variable risk across emerging tech(12:51) How to insure the growing Cybersecurity space(17:43) How does Relm assess risk for a company(19:28) AWS outage(22:28) Why Founders should prioritize insurance against risk(24:30) Relm roadmap for 2025 and 2026(28:30) UI/UX in Web3(30:31) Events & conferences(32:12) Learn more & contact Relm

Join January Jones and co-host Isabel Castro in this episode of Hot Topics on the Edge of Show as they dive into the latest developments in the crypto world. This week, they discuss the recent AWS outage that disrupted major crypto platforms like MetaMask and Coinbase, raising questions about the true decentralization of these services.They also explore A16z's State of Crypto 2025 report, highlighting the rise of corporate and private blockchains and the emergence of cross-chain solutions. Unique Divine from Nibiru joins the conversation to share insights about his high-performance layer one blockchain designed for cross-chain DeFi, discussing the importance of sustainable yield and the future of decentralized finance.Tune in for an engaging discussion on the evolving landscape of Web3 technology, the challenges of decentralization, and what lies ahead for the crypto industry!Topics Covered:AWS outage and its impact on crypto platformsThe state of decentralization in the crypto spaceA16z's State of Crypto 2025 report highlightsThe rise of corporate blockchains and cross-chain solutionsUnique Divine's insights on Nibiru and sustainable yieldDon't forget to subscribe and follow us on social media to stay updated on the latest episodes and discussions!Support us through our Sponsors! ☕

Send us a textIn this episode of Small Cap Spotlight x WTR Healthcare Happenings podcast, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla's strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Live from Token2049, The Edge of Show brings together four industry leaders shaping the future of Web3 infrastructure, decentralized networks, and global finance.Avery Ching, CEO of Aptos, discusses how scalable Layer 1 architecture and real-world applications are redefining blockchain adoption. Frank Mong from Helium shares how DePIN is powering decentralized connectivity and the next evolution of wireless networks. Saad Ahmed, Head of Asia Pacific at Gemini, dives into institutional crypto growth across Asia and what's next for regulatory clarity. And Will Fey of Ammalgam explores how liquidity and data flow are evolving to connect decentralized and traditional finance.A forward-looking conversation on scalability, interoperability, and innovation at the core of Web3's next phase.Support us through our Sponsors! ☕

Welcome to this episode of Hot Topics on the Edge of Show! Join hosts January Jones and Josh Krieger as they dive into the latest developments in the cryptocurrency world with special guest Josh Lawler from Zuber Lawler.In this episode, we discuss:The recent crypto market crash triggered by President Trump's announcement of a 100% tariff on Chinese imports, leading to significant liquidations and market volatility.The proactive response from Binance, one of the world's largest exchanges, as they offer compensation to affected users.The current status of U.S. crypto legislation amidst the ongoing government shutdown and the implications for the future of the industry.A major $14.2 billion seizure of Bitcoin linked to a vast network of human trafficking and crypto scams, and the questions surrounding victim reparations.Insights into the upcoming Future of Money, Governance, and the Law Summit on October 29th and 30th in Washington, D.C., featuring key players from the crypto industry and government.Don't miss this engaging discussion filled with expert insights and analysis on the evolving landscape of cryptocurrency and regulation.Subscribe to our channel for more episodes and follow us on social media to stay updated on the latest trends in Web3 technology, culture, and innovation!Event Website: https://gbaglobal.org/fomgl/ for summit tickets and more information.Support us through our Sponsors! ☕

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.